Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Tumor Lysis Syndrome: Incidence, Mitigation and Management in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice (DEVOTE) across Canada

Versha Banerji, Nizar Abdel-Samad, Andrew Aw, Sarah-Jane Bull, Pierre-André Fournier, Nathalie Johnson, Nicole B. Laferriere, Paola Lembo, Christina H Pelizon, Anthea Peters, Carolyn Owen

Blood (2021) 138 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2021-146001

Published: 2021

Journal Articles

Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

Philippe Armand, Pier Luigi Luigi Zinzani, Hun Ju Lee, Nathalie Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz

Blood (2021) 138 (Supplement 1): 1366.

https://doi.org/10.1182/blood-2021-147881

Published: 2021

Journal Articles

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Blood (2019) 134 (Supplement_1): 921.

https://doi.org/10.1182/blood-2019-127399

Published: 2019

Journal Articles

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie Johnson, MD, Pauline Brice, John Radford, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, MD PhD, Bastian Von Tresckow, Margaret A. Shipp, MD, Alex F. Herrera, MD, Jianxin Lin, Eunhee Kim, Mohammed Farooqui, Patricia Marinello, Craig H. Moskowitz

Blood (2019) 134 (Supplement_1): 240.

https://doi.org/10.1182/blood-2019-127280

Published: 2019

Journal Articles

Changes in Tumor Immune Micro-Environment in Diffuse Large B-Cell Lymphoma (DLBCL): A Comparative Study of Relapsed Versus Diagnostic DLBCL

Raoul Santiago, MDMSc, Nathalie Johnson, MD, Svetlana Dmitrienko, MD PhD, Andreas Papadakis, PhD, Naciba Benlimame, PhD, François Mercier, MD, Koren Kathleen Mann, PhD, Sarit Assouline, MD

Blood (2019) 134 (Supplement_1): 3968.

https://doi.org/10.1182/blood-2019-122207

Published: 2019

Journal Articles

A 10-Color Flow Cytometry Panel for Both Diagnosis and Minimal Residual Disease Measurement in Chronic Lymphocytic Leukemia

Alexandre Bazinet, MD, Ryan N Rys, BSc, BA, Claudia M Wever, PhD, Amadou Barry, Celia Greenwood, PhD, Christian Young, Alma Mendoza, Ida LaPorta, Sylvain Gimmig, François Mercier, MD, Nathalie Johnson, MD

Blood (2019) 134 (Supplement_1): 5451.

https://doi.org/10.1182/blood-2019-123904

Published: 2019

Journal Articles

Evaluation of T-Cell Compartment By Complex Multiparameter Flow Cytometry Reveals Distinct Patterns of T-Cell Exhaustion in DLBCL, FL and HL Patients

Alexis Vallée, Mitra Shourian, PhD, Nathalie Johnson, MD, Hélène Decaluwe

Blood (2019) 134 (Supplement_1): 2806.

https://doi.org/10.1182/blood-2019-130647

Published: 2019

Journal Articles

Fas Mutations in Non-Hodgkin's Lymphoma (NHL): Implications for Disease Progression and Therapeutic Resistance

Ryan N Rys, BSc, BA, Maanasa Venkataraman, MSc, Jibin Zeng, MSc, Koren Kathleen Mann, PhD, Nathalie Johnson, MD

Blood (2019) 134 (Supplement_1): 1520.

https://doi.org/10.1182/blood-2019-130602

Published: 2019

Journal Articles

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1478.

https://doi.org/10.1182/blood-2019-129136

Published: 2019

Journal Articles

CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas

Ryan N Rys, BSc, BA, Dominique Geoffrion, BSc, Christopher Rushton, BSc, Miguel Alcaide, PhD, Raoul Santiago, MDMSc, Koren Kathleen Mann, PhD, Svetlana Dmitrienko, MD PhD, Tina Petrogiannis-Haliotis, MD PhD, Sarit Assouline, MD, Ryan D. Morin, PhD, Nathalie Johnson, MD

Blood (2019) 134 (Supplement_1): 1608.

https://doi.org/10.1182/blood-2019-127129

Published: 2019

Journal Articles

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

Blood (2016) 128 (2): 185–194.

https://doi.org/10.1182/blood-2016-02-699520

Published: 2016

Includes: Supplemental data

Journal Articles

A Randomized, Phase II Study with Biomarker Analysis of Panobinostat with or without Rituximab in Relapsed Diffuse Large B Cell Lymphoma

Sarit Assouline, Michael Crump, MD, Torsten Holm Nielsen, Miguel Alcaide, B. Sc., Ph. D., David Macdonald, MD FRCPC, Axel Tosikyan, Tina Haliotis, Celia Greenwood, Kathleen Klein Oros, Ryan Morin, PhD, Nathalie Johnson, MD PhD, Koren Kathleen Mann, PhD

Blood (2015) 126 (23): 2719.

https://doi.org/10.1182/blood.V126.23.2719.2719

Published: 2015

Journal Articles

Disruption of Direct 3-Dimensional (3D) Telomere-TRF2 (Telomere Related Factor 2) Interaction Is a Hallmark of Primary Hodgkin (H) and Reed-Sternberg (RS) Cells

Hans Knecht, MD, Nathalie Johnson, MD PhD, Tina Petrogiannis-Haliotis, MD PhD, Daniel Lichtensztejn, Sabine Mai, PhD

Blood (2015) 126 (23): 177.

https://doi.org/10.1182/blood.V126.23.177.177

Published: 2015

Journal Articles

An RCOR1 loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup

Blood (2015) 125 (6): 959–966.

https://doi.org/10.1182/blood-2013-06-507152

Published: 2015

Includes: Supplemental data

Journal Articles

The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL)

Kerry J. Savage, MDMSc, Laurie H. Sehn, MDMPH, Diego Villa, MDMPH, Roopesh R. Kansara, MD, Anja Mottok, MD, Daisuke Ennishi, MDPhD, Susana Ben-Neriah, MSc, Robert Kridel, MDMPH,, Christian Steidl, MD, King L. Tan, MBBS, Nathalie Johnson, MDPhD, Graham W. Slack, MD, Joseph M. Connors, MD, Pedro Farinha, MD, David W. Scott, MBChB, PhD, Randy D. Gascoyne, MD

Blood (2014) 124 (21): 495.

https://doi.org/10.1182/blood.V124.21.495.495

Published: 2014

Journal Articles

FAS Mutations Accelerate Lymphoma Growth and Induce Therapeutic Resistance

Stephanie Totten, B.Sc., Denis Gaucher, PhD, Ryan D Morin, PhD, Sarit Assouline, MD MSc, Joseph M. Connors, MD, Marco A. Marra, PhD, David W. Scott, MBChB, PhD, Randy D. Gascoyne, MD, Jerry Pelletier, PhD, Koren K Mann, PhD, Nathalie Johnson, MD PhD

Blood (2014) 124 (21): 3018.

https://doi.org/10.1182/blood.V124.21.3018.3018

Published: 2014

Journal Articles

Large-Scale High Resolution Integration of Copy Number and Gene Expression in DLBCL Reveals Focal and Frequent Deletions in Chromatin Modifying Genes with Outcome Correlation

Fong Chun Chan, MSc, Susana Ben-Neriah, Raymond Lim, MSc, Sandy Hu, Sanja Rogic, PhD, Nathalie Johnson, MD, Ryan D Morin, PhD, Gavin Ha, Jiraui Ding, MSc, David W. Scott, MBChB PhD, Laurie H. Sehn, MD, Joseph M. Connors, MD, Marco A. Marra, PhD, Randy D. Gascoyne, MD, Sohrab P Shah, PhD, Christian Steidl, MD

Blood (2012) 120 (21): 295.

https://doi.org/10.1182/blood.V120.21.295.295

Published: 2012

Journal Articles

FAS Mutations Are Associated with Therapeutic Resistance in Follicular Lymphoma

Nathalie Johnson, MD, PhD, Denis Gaucher, PhD, Hawley Rigsby, Ryan D Morin, PhD, Joseph M. Connors, MD, Marco Marra, PhD, Randy D. Gascoyne, MD

Blood (2012) 120 (21): 1549.

https://doi.org/10.1182/blood.V120.21.1549.1549

Published: 2012

Journal Articles

Targeting EVI1-Overexpressing AML with Darinaparsin

Koren K Mann, PhD, Nathalie Johnson, MD, Torsten Holm Nielsen, MD, Nicolas Garnier, MSc, Stanley Kwan, Eftihia Cocolakis, PhD, Josee Hebert, MD, Robert Morgan, MSc, Wilson H. Miller, Jr., MD, PhD

Blood (2011) 118 (21): 4269.

https://doi.org/10.1182/blood.V118.21.4269.4269

Published: 2011

Journal Articles

Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis

Nyasha Chambwe, BS, Matthias Kormaksson, Ph.D, Subhajyoti De, Ph.D., Franziska Michor, Ph.D., Nathalie Johnson, MD, David W Scott, MBChB PhD, Randy D. Gascoyne, MD, Ari Melnick, MD, Fabien Campagne, Ph.D., Rita Shaknovich, MD/PhD

Blood (2011) 118 (21): 556.

https://doi.org/10.1182/blood.V118.21.556.556

Published: 2011

NARROW

Tumor Lysis Syndrome: Incidence, Mitigation and Management in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice (DEVOTE) across Canada

Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Changes in Tumor Immune Micro-Environment in Diffuse Large B-Cell Lymphoma (DLBCL): A Comparative Study of Relapsed Versus Diagnostic DLBCL

A 10-Color Flow Cytometry Panel for Both Diagnosis and Minimal Residual Disease Measurement in Chronic Lymphocytic Leukemia

Evaluation of T-Cell Compartment By Complex Multiparameter Flow Cytometry Reveals Distinct Patterns of T-Cell Exhaustion in DLBCL, FL and HL Patients

Fas Mutations in Non-Hodgkin's Lymphoma (NHL): Implications for Disease Progression and Therapeutic Resistance

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

A Randomized, Phase II Study with Biomarker Analysis of Panobinostat with or without Rituximab in Relapsed Diffuse Large B Cell Lymphoma

Disruption of Direct 3-Dimensional (3D) Telomere-TRF2 (Telomere Related Factor 2) Interaction Is a Hallmark of Primary Hodgkin (H) and Reed-Sternberg (RS) Cells

An RCOR1 loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup

The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL)

FAS Mutations Accelerate Lymphoma Growth and Induce Therapeutic Resistance

Large-Scale High Resolution Integration of Copy Number and Gene Expression in DLBCL Reveals Focal and Frequent Deletions in Chromatin Modifying Genes with Outcome Correlation

FAS Mutations Are Associated with Therapeutic Resistance in Follicular Lymphoma

Targeting EVI1-Overexpressing AML with Darinaparsin

Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only